Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 11;220(2):e20221333. doi: 10.1084/jem.20221333

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Zhou et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S1. — Flow cytometry gating strategy for colonic LP immune cells and scRNAseq analysis of colonic LP immune cells following αCTLA-4 therapy. (A) Gating strategy of colonic LP lymphoid cell subsets. (B) Gating strategy of colonic LP myeloid cell subsets. (C–E) Stat3^Δ/Δ and Stat3^+/+ mice bearing B16-OVA tumors were treated biweekly for 2 wk with IgG or αCTLA-4. Colonic LP immune cells were subjected to scRNAseq as indicated in Fig. 2; n = 7–8 per group. (C) Distinct composition of colonic LP immune cell populations in mice of indicated genotypes and treatments (left), with expanded view of myeloid clusters (right). (D) Feature plots of selected cluster-defining genes. (E) Heatmap of the top five differentially expressed genes in each cluster.